Equities

Genoway SA

Genoway SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)3.48
  • Today's Change-0.14 / -3.87%
  • Shares traded5.26k
  • 1 Year change-13.22%
  • Beta0.4653
Data delayed at least 15 minutes, as of Nov 12 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments4.264.885.61
Total Receivables, Net121412
Total Inventory0.981.190.98
Prepaid expenses0.230.170.25
Other current assets, total------
Total current assets182019
Property, plant & equipment, net5.886.677.17
Goodwill, net0.200.200.20
Intangibles, net5.465.335.25
Long term investments2.250.580.55
Note receivable - long term------
Other long term assets0.330.330.16
Total assets323333
LIABILITIES
Accounts payable2.582.622.22
Accrued expenses2.331.871.75
Notes payable/short-term debt0.010.010.01
Current portion long-term debt/capital leases1.701.841.83
Other current liabilities, total1.982.642.73
Total current liabilities8.618.978.52
Total long term debt5.527.208.99
Total debt7.239.0511
Deferred income tax------
Minority interest------
Other liabilities, total0.331.390.58
Total liabilities141818
SHAREHOLDERS EQUITY
Common stock5.565.455.45
Additional paid-in capital9.149.229.22
Retained earnings (accumulated deficit)0.84(0.73)(1.51)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.841.431.41
Total equity171515
Total liabilities & shareholders' equity323333
Total common shares outstanding8.808.788.78
Treasury shares - common primary issue0.250.270.26
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.